FOXP3 and coronary artery disorder: SSLK intervention may improve CHD symptoms of the patients by increasing the percentage of CD4+CD25+FoxP3 Treg cells and reducing the percentage of CD4+IL-17 cells in PBMCs and maintained their balance (Figure 6).